# Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer

> **NCT05009953** · PHASE2 · TERMINATED · sponsor: **CSPC Ouyi Pharmaceutical Co., Ltd.** · enrollment: 17 (actual)

## Conditions studied

- Advanced Biliary Tract Cancer
- Intrahepatic Cholangiocarcinoma
- Extrahepatic Cholangiocarcinoma
- Gallbladder Carcinoma

## Interventions

- **DRUG:** Irinotecan Liposome Injection
- **DRUG:** SG001
- **DRUG:** Fluorouracil
- **DRUG:** Leucovorin

## Key facts

- **NCT ID:** NCT05009953
- **Lead sponsor:** CSPC Ouyi Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-09-01
- **Primary completion:** 2023-01-16
- **Final completion:** 2023-01-16
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** Internal strategy change. Not related to safety concerns.
- **Last updated:** 2024-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05009953

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05009953, "Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05009953. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*